ABSTRACT NUMBER: ESOC2026LT72 LT72 - EARLY ANTIPLATELET THERAPY VERSUS LATE ANTIPLATELET THERAPY IN ACUTE ISCHEMIC STROKE PATIENTS WITH HEMORRHAGIC INFARCTION AFTER INTRAVENOUS THROMBOLYSIS (HITS): A RANDOMIZED CONTROLLED TRIAL

Abstract Background and aims Hemorrhagic infarction (HI) is the most common hemorrhagic transformation subtype after intravenous thrombolysis (IVT) for acute ischemic stroke (AIS), but optimal antiplatelet timing remains undefined. We aimed to determine whether early antiplatelet (EA) therapy improves functional outcomes without raising hemorrhagic risk. Methods In this randomised, multicenter, open-label, blinded-endpoint trial (HITS), patients were recruited from 41 stroke centres across China. AIS Patients were eligible if they treated with IVT within 24 hours of symptom onset, confirmed with HI on CT 24-36 hours post-IVT, and had no aspirin contraindications. Eligible patients were randomly assigned (1:1) to EA therapy (aspirin initiated within 24-48 hours post-IVT) or late antiplatelet (LA) therapy (antiplatelet therapy delayed beyond 48 hours after stroke onset). The primary outcome was the proportion of patients with a modified Rankin Scale (mRS) score of 0-2 at 90 days. Results Finally, 294 participants were randomly assigned to EA group (n=146) or LA group (n=148). The EA group had a significantly higher proportion of mRS 0-2 at 90 days (59.7% vs. 44.8%; adjusted risk ratio 1.259, 95% CI 1.005–1.580) compared with the LA group. No significant between-group differences were observed in 7-day symptomatic intracerebral hemorrhage, early neurological deterioration, hemorrhagic transformation expansion, or 90-day mortality. Recurrent acute ischemic stroke within 90 days occurred in 2 (1.4%) patients in both groups. Conclusions The HITS trial demonstrated that EA therapy initiated within 24-48 hours post IVT improves functional outcomes in post-IVT HI patient, without increasing hemorrhagic risk, providing definitive evidence to optimizing post-thrombolysis treatment. Conflict of interest

Authors

Institutions

Publication Details

Journal
European Stroke Journal
Published
2026-05-01
DOI
https://doi.org/10.1093/esj/aakag023.1886
Primary Topic
Acute Ischemic Stroke Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

ABSTRACT NUMBER: ESOC2026LT72 LT72 - EARLY ANTIPLATELET THERAPY VERSUS LATE ANTIPLATELET THERAPY IN ACUTE ISCHEMIC STROKE PATIENTS WITH HEMORRHAGIC INFARCTION AFTER INTRAVENOUS THROMBOLYSIS (HITS): A RANDOMIZED CONTROLLED TRIAL

Shenqiang Yan, Wansi Zhong, Z Y Chen, Yaode He et al.
European Stroke Journal
Acute Ischemic Stroke Management
article

ABSTRACT NUMBER: ESOC2026LT72 LT72 - EARLY ANTIPLATELET THERAPY VERSUS LATE ANTIPLATELET THERAPY IN ACUTE ISCHEMIC STROKE PATIENTS WITH HEMORRHAGIC INFARCTION AFTER INTRAVENOUS THROMBOLYSIS (HITS): A RANDOMIZED CONTROLLED TRIAL

Shenqiang Yan, Wansi Zhong, Z Y Chen, Yaode He, Jie Yang, Xi Zhang, Yuehua Chen, Y Zhou, Kemeng Zhang, Haitao Hu, Min Lou
article en

Abstract

Abstract Background and aims Hemorrhagic infarction (HI) is the most common hemorrhagic transformation subtype after intravenous thrombolysis (IVT) for acute ischemic stroke (AIS), but optimal antiplatelet timing remains undefined. We aimed to determine whether early antiplatelet (EA) therapy improves functional outcomes without raising hemorrhagic risk. Methods In this randomised, multicenter, open-label, blinded-endpoint trial (HITS), patients were recruited from 41 stroke centres across China. AIS Patients were eligible if they treated with IVT within 24 hours of symptom onset, confirmed with HI on CT 24-36 hours post-IVT, and had no aspirin contraindications. Eligible patients were randomly assigned (1:1) to EA therapy (aspirin initiated within 24-48 hours post-IVT) or late antiplatelet (LA) therapy (antiplatelet therapy delayed beyond 48 hours after stroke onset). The primary outcome was the proportion of patients with a modified Rankin Scale (mRS) score of 0-2 at 90 days. Results Finally, 294 participants were randomly assigned to EA group (n=146) or LA group (n=148). The EA group had a significantly higher proportion of mRS 0-2 at 90 days (59.7% vs. 44.8%; adjusted risk ratio 1.259, 95% CI 1.005–1.580) compared with the LA group. No significant between-group differences were observed in 7-day symptomatic intracerebral hemorrhage, early neurological deterioration, hemorrhagic transformation expansion, or 90-day mortality. Recurrent acute ischemic stroke within 90 days occurred in 2 (1.4%) patients in both groups. Conclusions The HITS trial demonstrated that EA therapy initiated within 24-48 hours post IVT improves functional outcomes in post-IVT HI patient, without increasing hemorrhagic risk, providing definitive evidence to optimizing post-thrombolysis treatment. Conflict of interest

European Stroke JournalVol. 11(Supplement_1)
Second Affiliated Hospital of Zhejiang University (CN)
Good health and well-being
Openalex Percentile: Top 9%
Acute Ischemic Stroke Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.